![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA APPROVES SALIX'S MOVIPREP
FDA APPROVES SALIX'S MOVIPREP
August 4, 2006
Salix Pharmaceuticals announced that the FDA has granted marketing approval for prescription MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution). MoviPrep is indicated for bowel cleansing prior to colonoscopy.
Salix licensed exclusive rights to MoviPrep in the United States from Norgine, which has filed a patent application for the drug that, if granted, would provide protection until 2023.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct